Pheochromocytoma is a catecholamine -producing tumor of the adrenergic system or the chromaffin cells among which approximately 90% are adrenomedullary. Non-adrenal tumors are also found which arise from the sympathetic nervous system. These are designated as extra-adrenal pheochromocytomas or functioning paragangliomas and they most commonly occur in the abdomen, chest and neck. Pheochromocytomas are rare in nature and it occurs in 1 to 2 people out of 100,000 adults.
Symptoms include hypertension (paroxysmal or persistent), headache, pallor, hyperhidrosis, anxiety, tachycardia, palpitations, angina, hyperglycemia, weight loss, paresthesias, visual disturbances (second-degree hypertensive retinopathy), dilated pupils are observed according to the secretions of catecholamines by the tumor. Other than these, events like vasoconstriction can occur due to alpha-adrenergic stimulation, a decrease in insulin secretion is observed by alpha2- adrenergic stimulation. Similarly, cardiac inotropy, bronchodilation, vasodilation and others can be observed. Cardiomyopathy may also be observed due to excessive levels of catecholamines. are toxic to the myocardium and cardiomyopathy may result. The symptoms can be episodic in nature. Paroxysms may last from less than 1 min to several hours and may occur only once every few months or as frequently as multiple times per day.
1. Checking the above-mentioned symptoms is important as the first step of diagnosis. Other than this pressor response to histamine, glucagon, droperidol, tyramine, metoclopramide, saralasin, tricyclic antidepressants, or phenothiazines also indicate the possibility of pheochromocytoma.
2. Patients when examined physically may be observed to be normal apart from the occurrence of paroxysm.
3. In order to confirm through laboratory evaluation plasma or urinary catecholamine levels or urinary catecholamine metabolite (VMA or metanephrine) levels are checked. In rare cases, suppression tests (clonidine) or provocative tests (glucagon) are needed.
4. The levels of plasma and urinary catecholamines can be interfered by stimulation of endogenous catecholamines (e.g., surgery, stroke) or administration of exogenous catecholamines which may include various drugs (alpha2-agonists, methyldopa, converting enzyme inhibitors and others)
5. Tumors may also be localized by scanning techniques like CT, MRI, or venous blood sampling for catecholamines.
6. The differential diagnosis includes the symptoms of malignant hypertension, thyrotoxic crisis, hypertensive response (to stress, surgery, anesthesia) and so on.
Considering the treatment approaches for pheochromocytoma, surgical excision is meant to be the definitive treatment which requires preoperative management in order to determine the surgical outcome. The preoperative goals include controlling blood pressure, providing adequate intravascular volume, treating tachyarrhythmias, treating heart failure and glucose intolerance. Other than these measures like adequate amounts of blood should be available for transfusion in the perioperative period because bleeding is frequently observed, diuretics should be used sparingly as intravascular volume is already constricted by catecholamines, drugs that releases catecholamine are to be avoided. Postoperative monitoring of cardiovascular and metabolic activities are required. Meperidine, and benzodiazepines can be used for sedation and pain. In the case of recurrent hypertension after operation the possibility of residual tumor needs to be checked.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
EU Flags Shortage Of Schizophrenia Drug Injections Due to Manufacturing Issues
2.
Universal screening approach achieves a comparable detection rate of lung cancer
3.
GLP-1 drugs linked to dramatically lower death rates in colon cancer patients
4.
The response of bipolar patients to lithium may be predicted by ancestry.
5.
Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study
1.
Aging of Bone-Marrow Immune Niches: Mechanisms, Clinical Impact, and Therapeutic Horizons
2.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
3.
Skin-Sparing Mastectomy: Balancing Cancer Control with Cosmetic Results
4.
Precision Supportive Oncology: Managing Immune Toxicity, Treatment-Related Critical Illness and Long-Term Quality of Life
5.
Environmental Carcinogen Exposure Risk Modeling: Current Evidence and Clinical Implications
1.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Symposium on Oncology, Cardiology and Critical Care Innovations
4.
International Conference on Cancer Nursing and Hematology Support
5.
International Conference on Clinical Medicine and Surgical Care
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
Understanding the Role of Screening in Cancer Prevention
3.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XII
5.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation